Charles S. Fuchs

Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study

    KEYNOTE062 (NCT02494583) was a randomized, active controlled study of first-line (1L) pembrolizumab (P) or pembrolizumab plus chemotherapy (P+C) vs chemotherapy (C) in pts...

Charles S. Fuchs ;

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

07/01/2019

Research Reports

Patterns and Predictors of Treatment Choice in a Real-World Cohort of Patients with Metastatic Gastric Cancer in the United States

09/22/2021

Sui Zhang , MS, MPP;

Astra M. Liepa , PharmD;

Lisa M. Hess , PhD;

Gary Meyer , PhD;

Thomas A. Abrams , MD;

Peter C. Enzinger , MD;

Jeffrey A. Meyerhardt , MD, MPH;

Charles S. Fuchs ;

Deborah Schrag , MD, MPH;

Yajun Zhu , MS;

Thomas A. Abrams, MD, and colleagues examine patterns of systemic therapy administration in metastatic gastric cancer and the predictors associated with specific treatment choices.

Thomas A. Abrams, MD, and...

09/22/2021

Journal of Clinical Pathways